Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cinclus Pharma Holding ABFRA:J8P -4.93%6 PB Ratio is 1.86 as of Jul. 18, 2026, which is 4% above its 10-year median of 1.78. GuruFocus rates FRA:J8P with a GF Score™ of 6/100. The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, Cinclus Pharma Holding AB ranks worse than 51.41% on this metric.
The historical rank and industry rank for Cinclus Pharma Holding AB's PB Ratio or its related term are showing as below:
FRA:J8P'
s PB Ratio Range Over the Past 10 Years
Min: 0.89 Med: 1.78 Max: 2.86
Current: 1.98
During the past 5 years, Cinclus Pharma Holding AB's highest PB Ratio was 2.86. The lowest was 0.89. And the median was 1.78.
FRA:J8P's PB Ratio is ranked worse than 51.41% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs FRA:J8P: 1.98
During the past 12 months, Cinclus Pharma Holding AB's average Book Value Per Share Growth Rate was -45.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 42.80% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Cinclus Pharma Holding AB was 63.50% per year. The lowest was 42.80% per year. And the median was 53.15% per year.
Back to Basics: PB Ratio
Cinclus Pharma Holding AB (FRA:J8P) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cinclus Pharma Holding AB PB Ratio Related Terms
Cinclus Pharma Holding AB PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cinclus Pharma Holding AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cinclus Pharma Holding AB PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cinclus Pharma Holding AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cinclus Pharma Holding AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cinclus Pharma Holding AB (FRA:J8P) has a PB Ratio of 1.86 as of Jul. 18, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cinclus Pharma Holding AB and its competitors. This is near median its historical median of 1.78. Over the past decade, Cinclus Pharma Holding AB's PB Ratio has ranged from 0.89 to 2.86. According to the industry distribution chart, Cinclus Pharma Holding AB ranks #474 out of 922 companies in the Drug Manufacturers industry, placing it in the top 51.4%.
Is Cinclus Pharma Holding AB's PB Ratio too high?
Cinclus Pharma Holding AB's current PB Ratio of 1.86 is near median its 10-year median of 1.78. Over the past 10 years, this metric has ranged from a low of 0.89 to a high of 2.86. The Drug Manufacturers industry median PB Ratio is 1.91. Cinclus Pharma Holding AB's value of 1.86 is 2.6% below this industry median. Based on the distribution chart, Cinclus Pharma Holding AB ranks #474 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cinclus Pharma Holding AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cinclus Pharma Holding AB ranks #474 out of 922 companies for PB Ratio. This places Cinclus Pharma Holding AB in the lower half of its industry. The industry median PB Ratio is 1.91. Cinclus Pharma Holding AB's value of 1.86 is 2.6% below this benchmark. Historically, Cinclus Pharma Holding AB's own PB Ratio has ranged from 0.89 to 2.86 over the past decade. While the company's 10-year median is 1.78 vs. the industry median of 1.91, Cinclus Pharma Holding AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cinclus Pharma Holding AB's current PB Ratio of 1.86 is 2.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cinclus Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cinclus Pharma Holding AB's current PB Ratio is 1.86, which is near median its own 10-year median of 1.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current PB Ratio of 1.86. The current PB Ratio is 1.86, which is near median its 10-year median of 1.78 and 2.6% below the Drug Manufacturers industry median of 1.91. Cinclus Pharma Holding AB's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current PB Ratio is 1.86 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score
Get the complete analysis for FRA:J8P
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J8P has been successfully added to your 
